Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224-6823, USA.
Department of Neuroscience, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224-6823, USA.
Psychopharmacology (Berl). 2018 Feb;235(2):521-534. doi: 10.1007/s00213-017-4769-4. Epub 2017 Nov 7.
Although psilocybin and dextromethorphan (DXM) are hallucinogens, they have different receptor mechanisms of action and have not been directly compared.
This study compared subjective, behavioral, and physiological effects of psilocybin and dextromethorphan under conditions that minimized expectancy effects.
Single, acute oral doses of psilocybin (10, 20, 30 mg/70 kg), DXM (400 mg/70 kg), and placebo were administered under double-blind conditions to 20 healthy participants with histories of hallucinogen use. Instructions to participants and staff minimized expectancy effects. Various subjective, behavioral, and physiological effects were assessed after drug administration.
High doses of both drugs produced similar increases in participant ratings of peak overall drug effect strength, with similar times to maximal effect and time-course. Psilocybin produced orderly dose-related increases on most participant-rated subjective measures previously shown sensitive to hallucinogens. DXM produced increases on most of these same measures. However, the high dose of psilocybin produced significantly greater and more diverse visual effects than DXM including greater movement and more frequent, brighter, distinctive, and complex (including textured and kaleidoscopic) images and visions. Compared to DXM, psilocybin also produced significantly greater mystical-type and psychologically insightful experiences and greater absorption in music. In contrast, DXM produced larger effects than psilocybin on measures of disembodiment, nausea/emesis, and light-headedness. Both drugs increased systolic blood pressure, heart rate, and pupil dilation and decreased psychomotor performance and balance.
Psilocybin and DXM produced similar profiles of subjective experiences, with psilocybin producing relatively greater visual, mystical-type, insightful, and musical experiences, and DXM producing greater disembodiment.
虽然裸盖菇素和右美沙芬(DXM)都是致幻剂,但它们的作用机制不同,尚未直接进行比较。
本研究在最小化预期效应的条件下,比较了裸盖菇素和右美沙芬的主观、行为和生理效应。
20 名有使用致幻剂史的健康参与者接受了单次口服裸盖菇素(10、20、30mg/70kg)、右美沙芬(400mg/70kg)和安慰剂,采用双盲法给药。给参与者和工作人员的指示尽量减少预期效应。给药后评估各种主观、行为和生理效应。
两种药物的高剂量均导致参与者对药物峰值整体效应强度的评分相似增加,最大效应时间和时间进程相似。裸盖菇素在大多数以前对致幻剂敏感的参与者自评主观测量上产生有序的剂量相关增加。DXM 也产生了增加。然而,高剂量的裸盖菇素产生的视觉效果比 DXM 更显著、更多样,包括更大的运动和更频繁、更亮、更独特、更复杂(包括有纹理和万花筒)的图像和幻象。与 DXM 相比,裸盖菇素还产生了更大的神秘型和心理洞察力体验,以及对音乐的更大投入。相比之下,DXM 在解体感、恶心/呕吐和头晕方面产生的效果大于裸盖菇素。两种药物均增加了收缩压、心率和瞳孔扩张,降低了运动和平衡能力。
裸盖菇素和 DXM 产生了相似的主观体验模式,裸盖菇素产生了相对更大的视觉、神秘型、洞察力和音乐体验,而 DXM 则产生了更大的解体感。